Finland is the most advanced digital economy in the EU according to DESI* 2022 and Finnish health technology is globally renowned. While Finland’s population is relatively small, its strengths lie in the quality of its healthcare system, research infrastructure, and regulatory environment. The ability to conduct well-designed clinical trials and develop technologies in such an environment can lead to faster, more efficient development cycles and successful market entry, despite the size of the domestic market. Additionally, successful innovations in Finland can serve as a springboard for expansion into larger global markets.

*The Digital Economy and Society Index (DESI)

Why is Finnish medtech attracting global attention?

1: strong engineering and healthcare expertise

Finland boasts a high-quality healthcare system with advanced infrastructure and skilled healthcare professionals. This provides an ideal environment for testing and implementing new medical technologies.

2: regulatory experience in demanding markets

Well-established and transparent regulatory environment makes it easier for medtech companies to navigate the regulatory processes required for clinical trials and product approvals. Efficient regulatory pathways can accelerate the development and commercialisation of medical technologies.

3: close collaboration between clinics, universities and companies

Universities, biobanks, hospital districts, and several international pharmaceutical companies collaborate and invest in digital health infrastructure, creating a supportive environment for the development of healthcare technologies. This includes electronic health records, telemedicine, and other digital solutions that can facilitate the integration of new technologies.

4: strong engineering and healthcare expertise

Finland has a highly educated and skilled workforce, including professionals in healthcare, engineering, and technology. This talent pool is essential for the development, testing, and implementation of innovative medtech solutions.

5: access to international european markets

While Finland has a relatively small population, its proximity to other Nordic and European markets provides companies with access to a larger patient pool for clinical trials and a broader market for commercialisation.

6: supportive public funding and innovation programmes

The Finnish government actively supports research and development initiatives, offering grants, funding, and other incentives to promote innovation in various industries, including healthcare and medtech.

7: ethics and medical transparency

Finland is known for its commitment to ethical and transparent practices, which is crucial in clinical trials and healthcare research. This reputation enhances the credibility of studies conducted in the country.

8: international outlook from an early stage

Finland actively engages in international collaboration and partnerships, allowing medtech companies to benefit from global networks and expertise.
 

Sources: The Digital Economy and Society Index (DESI), FinnGen, Sailab – MedTech Finland ry, ITA .

What opportunities does Finnish medtech present for investors?

Startups in the MedTech industry often bring innovative solutions to healthcare problems, offering the potential for significant advancements in medical technology. 

The demand for new and improved medical technologies is consistently high as the healthcare industry seeks solutions for better diagnostics, treatment, and patient care. Emerging technologies may address unmet needs in the market creating opportunities for significant growth. Successful MedTech startups that bring disruptive technologies to market can yield high returns on investment, especially if the company is acquired by a larger healthcare corporation. 

FAQ

Does the strong medtech ecosystem in Finland make these investments less risky?

No. Even in a strong ecosystem, individual companies can fail and investors can lose all of their capital. Ecosystem‑level strengths do not remove company‑specific, clinical, regulatory or commercial risks.

Are Finnish medtech companies already approved in major markets?

Regulatory status varies by company and product. Some may have approvals or clearances in certain jurisdictions, others are still in development. Always check the latest company documentation and regulatory disclosures.

Is this article recommending that I invest in Finnish medtech companies?

No. It highlights structural strengths and trends in the ecosystem, but it is not a recommendation or personalised investment advice. Each potential investment should be assessed on its own merits and risks.

How should investors think about diversification in medtech?

Many investors spread their exposure over several companies and sectors, and combine medtech with other industries and asset classes. Diversification can help manage risk but does not guarantee returns.